Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12555211 | 0.92 | KMT2A (0.47) | KMT2AMEN1CASP3MDM2FABP5 | |
| SCHEMBL29470540 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2PTPN1 | |
| SCHEMBL1000962 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2PTPN1 | |
| SCHEMBL3367289 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2PTPN1 | |
| SCHEMBL31146900 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2PTPN1 | |
| SCHEMBL1745934 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2PTPN1 | |
| SCHEMBL29368397 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2PTPN1 | |
| SCHEMBL8410923 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2FABP5 | |
| SCHEMBL17192730 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2FABP5 | |
| SCHEMBL4395836 | 0.89 | KMT2A (0.45) | KMT2AMEN1CASP3MDM2FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878725-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040242656-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1289950-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030078438-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078438-A1 | Serine protease inhibitors | HPN, LPXN, PRSS1 | KMT2A 2897/4885MEN1 3220/4885CASP3 948/4885 |
| US-20040242656-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | KMT2A 3308/4885MEN1 1959/4885CASP3 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.